Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma
Luca Ielasi, Stefania De Lorenzo, Francesco Tovoli, Gianluca Svegliati‐Baroni et al.
Citations
5 citations
Journal
Digestive and Liver Disease
Topics
Hepatocellular Carcinoma Treatment and Prognosis
Field-Weighted Citation Impact (FWCI)
1.85
article
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma
Luca Ielasi, Stefania De Lorenzo, Francesco Tovoli, Gianluca Svegliati‐Baroni, Dante Pio Pallotta, Alessandro Granito, Piera Federico, Fabio Piscaglia, Caterina Vivaldi, Andrea Palloni, Claudia Campani, Sara Lonardi, Gianluca Masi, Bruno Daniele, Rusi Chen, Caterina Soldà, Giovanni Brandi, Ingrid Garajová, Bernardo Stefanini, Fabio Marra, Laura Schiadà, Lorenzo Lani, Andrea Dalbeni, A. Auriemma
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
Digestive and Liver DiseaseVol. 56(12)
Institutions
University of Verona (IT), University of Parma (IT), Ospedale degli Infermi (IT), Azienda Ospedaliero Universitaria Ospedali Riuniti (IT), Istituto Oncologico Veneto (IT), Azienda USL di Bologna (IT), Ospedale per gli Infermi (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Azienda Ospedaliera Universitaria Pisana (IT), University of Florence (IT), University of Bologna (IT)